Criteria for Operable Pancreatic Cancer

Classification and Operability Criteria

• The American College of Radiology recommends that pancreatic cancer is considered operable when there is no distant metastatic disease, no arterial involvement, and limited or reconstructable venous involvement, with the patient having adequate performance status to tolerate major surgery 1, 2
• The National Comprehensive Cancer Network classifies pancreatic ductal adenocarcinoma into three categories based on vascular involvement when metastases are absent, including resectable, borderline resectable, and locally advanced/unresectable disease 3, 1
• Resectable disease is defined as no arterial contact, minimal venous involvement, and no distant metastases, representing only 15-20% of patients at diagnosis 3, 1, 4
• Borderline resectable disease is characterized by limited arterial contact, venous involvement, and short-segment hepatic artery involvement, requiring neoadjuvant therapy before surgery 5, 2

Essential Staging Workup and Patient Selection

• The European Society for Medical Oncology recommends CT angiography with pancreatic protocol to assess vascular involvement, with each vessel assessed individually 3
• The American College of Radiology suggests MRI indications for problem-solving indeterminate hepatic lesions, cystic pancreatic neoplasms, or biliary anatomy evaluation 3
• The American Joint Committee on Cancer recommends tissue diagnosis via EUS-guided biopsy to provide complementary staging information and allow tissue sampling 3
• The National Comprehensive Cancer Network states that performance status must be adequate to tolerate major pancreatic surgery, with nutritional status requiring assessment and optimization pre-operatively 3, 6

Surgical Goals and Margins

• The Society of Surgical Oncology mandates R0 resection with negative margins, assessing seven margins including anterior, posterior, medial/superior mesenteric groove, SMA margin, pancreatic transection, bile duct, and enteric 1, 7, 6
• The American College of Surgeons accepts SMV-PV resection with reconstruction to achieve R0 resection, but notes it is associated with worse outcomes due to tumor aggressiveness 1, 2, 7

Critical Pitfalls to Avoid

• The American College of Radiology advises against operating on borderline resectable disease upfront, instead recommending neoadjuvant therapy first 1, 2, 7
• The European Society for Medical Oncology warns against attempting surgery with arterial involvement, as it predicts unresectability 3, 2
• The National Comprehensive Cancer Network recommends referral to high-volume centers, where resection rates are 20% higher and mortality significantly lower 6
• The American Joint Committee on Cancer suggests multidisciplinary evaluation to define optimal treatment strategy 6

Resectability Criteria and Management of Pancreatic Ductal Adenocarcinoma

1. Classification of Disease Based on Vascular Involvement

• Pancreatic ductal adenocarcinoma is divided into three categories—resectable, borderline resectable, and locally advanced/unresectable—according to the extent of arterial and venous involvement when distant metastases are absent. 8, 9, 10, 11

2. Resectable Disease (≈15‑20 % of patients at diagnosis)

• Arterial criterion: No tumor contact with the superior mesenteric artery, celiac axis, or common hepatic artery. 8
• Venous criterion: Either no tumor contact with the superior mesenteric vein (SMV) or portal vein (PV), or tumor contact involving < 180° of the vessel circumference without deformity or thrombosis. 8 [9]
• Outcome goal: Aim for an R0 resection (negative margins ≥ 1 mm). 8

3. Borderline Resectable Disease

• This intermediate category requires neoadjuvant therapy before surgery because upfront resection carries a high risk of positive (R1) margins. 8, 11

4. Locally Advanced / Unresectable Disease

• Arterial criterion: Tumor contact > 180° with the superior mesenteric artery or celiac axis defines locally advanced disease. 8, 11

5. Imaging and Vessel Assessment

• Individual vessel evaluation: The superior mesenteric artery, celiac axis, common hepatic artery, portal vein, and superior mesenteric vein must each be assessed separately. 8, 9, 10
• EUS‑guided biopsy: Provides tissue diagnosis and complementary staging information. 8
• Predictive values of cross‑sectional imaging: Contrast‑enhanced CT or MRI have > 90 % positive predictive value for unresectability but < 50 % positive predictive value for resectability, indicating they reliably exclude surgery but cannot definitively confirm it. 8, 9, 10, 11

6. Surgical Margin Assessment

• Seven margins should be examined after resection; the posterior surface margin is specifically highlighted. 10
• Venous resection: Resection and reconstruction of the SMV/PV are acceptable to achieve an R0 result, although such resections are linked to lower R0 rates and poorer survival because they reflect more aggressive tumor biology. 8
• Arterial resection: Not recommended due to substantially increased morbidity and mortality. 8, 9

7. Critical Pitfalls to Avoid

• Do not perform upfront surgery on borderline resectable cases; these patients have a high likelihood of R1 resection and should receive neoadjuvant therapy first. 8, 11
• Arterial involvement > 180° predicts unresectability and is associated with prohibitive postoperative morbidity and mortality. 8, 9

Imaging Guidelines for Assessing Operability in Pancreatic Cancer

Primary Imaging Modality

• Multidetector CT angiography with a dedicated pancreatic protocol is the gold‑standard technique for determining resectability in pancreatic cancer. 12
• Thin (sub‑millimeter) axial sections should be obtained using a dual‑phase technique: pancreatic/arterial phase at 40–50 s and portal‑venous phase at 65–70 s after contrast injection. 13
• CT demonstrates > 90 % positive predictive value for identifying unresectable disease, but < 50 % positive predictive value for confirming resectability. [@15@]

Classification Based on Vascular Involvement

• Arterial assessment: each major artery (superior mesenteric artery, celiac axis, common hepatic artery) must be evaluated individually for encasement or abutment. 12
• Venous assessment: tumor contact involving < 180° of the superior mesenteric or portal vein circumference without vessel deformation, thrombosis, or “tear‑drop” sign is compatible with resectability. 12
• Borderline‑resectable tumors require neoadjuvant therapy before surgery because of a high risk of R1 resection. 14
• Tumor contact > 180° with the superior mesenteric artery or celiac axis defines locally advanced/unresectable disease. 14
• Involvement of the celiac axis or superior mesenteric artery classifies the tumor as T4 (unresectable) according to TNM staging. 12

Additional CT Findings Relevant to Staging

• The primary tumor typically appears as a hypo‑attenuating, homogeneous mass with indistinct margins on the pancreatic arterial phase. 12
• Disruption of the biliary duct (with or without upstream dilatation) indicates tumor extension into the biliary tree. 12
• Systematic evaluation should include the liver for metastases, the peritoneum for nodules, and retro‑portal lymph nodes for enlargement. 12
• Any extra‑pancreatic extension into retroperitoneal structures must be explicitly described. 12

Complementary Imaging Modalities

• MRI provides staging performance equivalent to CT and offers no proven superiority; it is useful for evaluating cystic pancreatic lesions and biliary anatomy. 12

Role of Endoscopic Ultrasound (EUS)

• EUS adds complementary staging information with approximately 90 % sensitivity and 86 % specificity for predicting resectability. 12
• Fine‑needle aspiration via EUS yields about 95 % diagnostic accuracy for tissue confirmation. 12
• EUS can sample atypical lymph nodes to uncover distant metastases that would preclude resection. 12
• EUS should not be used routinely to assess vascular involvement because it is operator‑dependent and less accurate than CT. (NCCN recommendation) 13

Critical Pitfalls to Avoid

• Metal biliary stents must not be placed before completing the staging work‑up; if biliary drainage is required, a plastic stent should be used. (NCCN recommendation) 12
• Percutaneous biopsy is discouraged in potentially resectable cases because it does not alter management and may increase complications. 15
• Reliance on lymph‑node size alone is insufficient; EUS detection of metastatic nodes has only 69 % sensitivity and 81 % specificity. 12
• Although 70–85 % of CT‑classified resectable tumors are successfully resected, 15–30 % are found to be unresectable at surgery, underscoring the need for meticulous imaging review. (NCCN recommendation) 13

Standardized Reporting

• Radiology reports should follow standardized staging templates to ensure comprehensive documentation of tumor size, arterial and venous involvement, and TNM classification. (NCCN recommendation) 13
• Precise measurement of tumor burden and clear description of vascular encasement are essential components of the report. 12

Surgical Management of Pancreatic Ductal Adenocarcinoma

Resectability Classification

• Resectable disease accounts for approximately 15‑20 % of patients at diagnosis and is defined by the absence of tumor contact with the superior mesenteric artery, celiac axis, or common hepatic artery, and by either no venous involvement or tumor contact with less than 180° of the superior mesenteric or portal vein without deformity, thrombosis, or tear‑drop sign. Upfront surgery is the standard of care for this group. 16
• Borderline‑resectable disease is characterized by venous involvement of more than 180° of the superior mesenteric or portal vein or the presence of a tear‑drop deformation; these patients should receive neoadjuvant therapy before any surgical attempt. 16
• Locally advanced (unresectable) disease is defined by arterial tumor contact exceeding 180° with the superior mesenteric artery or celiac axis, or any arterial deformation/abutment, corresponding to T4 disease in the TNM classification. Surgery is contraindicated. [16][17]

Imaging and Staging Work‑up

• Multidetector CT angiography with a pancreatic protocol must assess each major vessel (SMA, celiac axis, common hepatic artery, portal vein, superior mesenteric vein) separately for encasement or abutment. [16][17]
• CT or MRI provide a > 90 % positive predictive value for unresectability but a < 50 % positive predictive value for resectability, making them reliable for ruling out surgery but not for confirming it. [16][17]
• An elevated serum CA 19‑9 level defines “biological borderline resectability” even when anatomic criteria suggest resectability, and should prompt consideration of neoadjuvant therapy. 17

Patient Selection Criteria

• Adequate performance status is mandatory for major pancreatic surgery; advanced age alone does not preclude operative treatment. 17
• Pre‑operative nutritional status must be evaluated and optimized, and all comorbid medical conditions require comprehensive assessment before proceeding to surgery. 17

Surgical Objectives and Technique

• The primary goal is an R0 resection with negative margins of at least 1 mm; only patients with a high probability of achieving R0 should be offered upfront surgery. [16][17]
• Pancreatoduodenectomy (Whipple procedure) is the recommended operation for tumors located in the pancreatic head. 16
• Pathologic assessment should include at least ten lymph nodes, and seven defined surgical margins (anterior, posterior, medial/superior mesenteric groove, SMA margin, pancreatic transection, bile duct, and enteric) must be examined. 17

Vascular Resection Considerations

• Resection and reconstruction of the superior mesenteric or portal vein is acceptable when required to achieve an R0 margin, although it is associated with lower R0 rates and poorer survival due to underlying tumor aggressiveness. 16
• Arterial resection is not recommended because of prohibitive morbidity and mortality.

Decision‑Making Algorithm (Evidence‑Based Steps)